Abstract:Rationale: Protein arginine methyltransferase 5 (PRMT5) is an oncogene that promotes tumor cell proliferation, invasion and metastasis. However, the underlying mechanisms by which PRMT5 contributes to the progression of cervical cancer and especially the tumor microenvironment remain poorly understood. Methods: PRMT5 expression level was analyzed by Q-PCR, western blot, immunohistochemistry, and TCGA database. The role of PRMT5 in tumor growth was observed by transplanted tumor models, and the function of T cells in tumor microenvironment and in vitro co-culture system was investigated through flow cytometry. The transcriptional regulation of PRMT5 was analyzed using luciferase reporter and chromatin immunoprecipitation (ChIP) assay. The therapeutic effect of PRMT5 inhibitor was evaluated in a cervical cancer cell line transplanted tumor model. Results: We observed that the mRNA and protein expression levels of PRMT5 were increased in cervical cancer tissues, and the high expression of PRMT5 was associated with poor outcomes in cervical cancer patients. The absence of PRMT5 significantly inhibited tumor growth in a cervical cancer transplanted tumor model, and importantly, PRMT5 absence in tumors led to increase the number and enhance the function of tumor infiltrating T cells. Mechanistically, PRMT5 enhanced the transcription of STAT1 through symmetric dimethylation of histone H3R2 and thus promoted PD-L1 expression in cervical cancer cells. Moreover, in an in vitro co-culture system, knockdown of PRMT5 in tumor cells could directly enhance the expression of IFN-γ, TNF-α and granzyme B in T cells. These results suggested that PRMT5 promoted the development of cervical cancer by the crosstalk between tumor cells and T cells. Furthermore, the PRMT5 inhibitor EPZ015666 treatment could suppress tumor growth in a cervical cancer transplanted tumor model. Conclusion: Our results clarify a new mechanism which PRMT5 knockdown in cervical cancer cells drives an antitumor function via reprogramming T cell-mediated response and regulating PD-L1 expression. Thus, our study highlights that PRMT5 may be a potential target for cervical cancer therapy.

Suppression of Tumorigenicity 5 Ameliorates Tumor Characteristics of Invasive Breast Cancer Cells Via ERK/JNK Pathway

The Tumor Suppressor Gene 5 in the Study of Differences in Regulatory Mechanisms and the Molecular Level in the Process of Human Gastric Cancer

The Epigenetic Modifier PRDM5 Functions As a Tumor Suppressor Through Modulating WNT/β-catenin Signaling and is Frequently Silenced in Multiple Tumors.

STAT5 confers lactogenic properties in breast tumorigenesis and restricts metastatic potential

Suppressor of Ty homolog-5, a novel tumor-specific human telomerase reverse transcriptase promoter-binding protein and activator in colon cancer cells

SIRT5 functions as a tumor suppressor in renal cell carcinoma by reversing the Warburg effect

PDLIM5 Inhibits STUB1-mediated Degradation of SMAD3 and Promotes the Migration and Invasion of Lung Cancer Cells.

STAT5A Modulates CDYL2/SLC7A6 Pathway to Inhibit the Proliferation and Invasion of Hepatocellular Carcinoma by Targeting to Mtorc1

Data from HMGN5 Escorts Oncogenic STAT3 Signaling by Regulating the Chromatin Landscape in Breast Cancer Tumorigenesis

PRMT5 disruption drives antitumor immunity in cervical cancer by reprogramming T cell-mediated response and regulating PD-L1 expression

Tumor Suppression of Ras GTPase-Activating Protein RASA5 Through Antagonizing Ras Signaling Perturbation in Carcinomas.

Chromodomain Helicase DNA Binding Protein 5 Plays a Tumor Suppressor Role in Human Breast Cancer

CMTM5 Exhibits Tumor Suppressor Activity Through Promoter Methylation in Oral Squamous Cell Carcinoma

SETD5 Promotes Tumor Progression and Induces Cancer Stem Cell-Like Properties Through Upregulation of AKT1 Signaling in Breast Cancer

Suppression Of The Proliferation And Invasion Of Breast Cancer Cells By St7l Occurs Through Inhibition Of Activation Of Wnt/Gsk-3 Beta/Beta-Catenin Signalling

MTH1 suppression enhances the stemness of MCF7 through upregulation of STAT3

PRMT5 Determines the Sensitivity to Chemotherapeutics by Governing Stemness in Breast Cancer

ING5 suppresses breast cancer progression and is regulated by miR-24

Promoter Methylation-Mediated Downregulation of PRDM5 Contributes to the Development of Lung Squamous Cell Carcinoma.

SET Domain-Containing Protein 5 Enhances the Cell Stemness of Non-Small Cell Lung Cancer via the PI3K/Akt/mTOR Pathway

Estrogen-Induced Interaction Between Klf5 And Estrogen Receptor (Er) Suppresses The Function Of Er In Er-Positive Breast Cancer Cells